SPINAL MUSCULAR ATROPHIES (SMA) are characterized by degeneration of lower motor neurons leading to progressive limb and trunk paralysis associated with muscular atrophy. SMA is a frequent recessive autosomal disorder caused by mutations of the survival of motor neuron gene (SMN1, incidence 1 of 5,000 -10,000 newborns; see Refs. 15 and 7 for review). SMN is a ubiquitously expressed protein of 294 amino acids with a molecular weight of 38 kDa. SMN forms a large multiprotein complex of ϳ1 MDa both in the cytoplasm and in the nucleus where it is concentrated in a structure called gems (for "gemini of coiled bodies"), most often associated with or identical to Cajal bodies (coiled bodies, Ref. 17) . The interaction of SMN with components of this large complex is enhanced by SMN oligomerization. The identification of SMN-interacting proteins of known function strongly supports the view that SMN is involved and facilitates cytoplasmic assembly of small nuclear ribonucleoprotein particle (snRNP) into the spliceosome, a large RNA-protein complex that catalyzes the splicing reaction (26) . In the nucleus, SMN appears to be directly involved in pre-mRNA splicing, transcription, and metabolism of ribosomal RNA (14, 22, 23) . SMN has also been shown to interact directly with other proteins including Bcl-2 and p53, two proteins involved in apoptotic processes, although these interactions and the involvement of an apoptotic process in SMA remain to be clarified in vivo (6, 13, 27) . Other direct or indirect partners of SMN include the far upstream element (FUSE)-binding protein, profilin II, a zinc finger protein called ZRP1, RNA helicase A, RNA polymerase II, RNA, and mSin3A (2, 9, 10, 20, 21, 25, 29) . Therefore, SMN appears to be a multifunctional protein.
A mouse line carrying two loxP sequences flanking Smn exon 7 (Smn F7 ) has been established through homologous recombination. Cre-mediated deletion of Smn exon 7 (Smn ⌬7 ) has been directed to either neurons or skeletal muscle ("neuronal" and "muscular" mutant, respectively; Refs. 4, 5, 8) . Neuronal mutant mice develop a severe motor defect leading to complete paralysis and death at a mean age of 1 mo (8) . Analysis of skeletal muscle revealed severe muscle denervation associated with a dramatic and progressive loss of motor axons contrasting with mild and late loss of motor neuron cell bodies. In addition, abnormal synaptic terminals filled with neurofilaments associated with defective axonal sprouting were observed at the neuromuscular junctions of mutant mice (5) . SMN has been studied in other organisms. Reduced levels of SMN in zebrafish or point mutations of SMN in Drosophila cause defects in motor axon pathfinding or neuromuscular junctions, respectively (3, 19) . Therefore, deficiency of SMN in various organisms has underlined an essential role of SMN for motor axon and neuromuscular junction development or maintenance. Surprisingly, homozygous deletion of Smn exon 7 directed to murine skeletal muscle only ("muscular mutant") led to a severe myopathic phenotype characterized by myofiber necrosis leading to muscle paralysis and death at a mean age of 1 mo (4). These data indicated that full-length SMN is essential for cell viability and showed that SMN ⌬7 is not able to compensate for lack of full-length SMN.
DNA chip technology is a powerful tool allowing the analysis of changes in expression of several thousand genes in parallel and the characterization of complex transcriptional activities. To determine downstream gene expression changes resulting from the Smn gene defect, gene expression profiles were analyzed in skeletal muscle and spinal cord of muscular and neuronal mutants, respectively, and compared with agematched controls. Comparison of gene expression profiles revealed an overexpression of RNA metabolism-related genes in both skeletal muscle and spinal cord of mutant mice but not in human SMA tissues.
MATERIALS AND METHODS
Animals. Muscular (HSA-Cre, Smn ⌬7/F7 ) or neuronal (NSE-Cre, Smn F7/F7 ) mutant mice were generated as previously described (4, 8) . Mice were maintained on C57BL/6J genetic background. Smn
animals from the same litter were used as controls. Transgenic mice expressing G93A mutation within the superoxide dismutase 1, cytosolic (SOD1) gene (11) and mdx mice were purchased from Jackson Laboratory and Charles River Laboratories (Arbresle, France), respectively. Animals were genotyped by PCR amplification of DNA extracted from tail biopsies (8, 11) . All animal procedures were performed with approval from the Veterinary Offices of the Essonne Department and from the Research Department of the Ministry of National Education, Research and Technology (agreement A91-228-2 and 3429).
Human tissues. Spinal cord (n ϭ 3) or skeletal muscle (n ϭ 3) from fetuses predicted for having SMA was collected. Spinal cord (n ϭ 5) or skeletal muscle (n ϭ 7) from fetuses of the same age and affected by a defect unrelated to neuromuscular disorders was used as controls. Prenatal diagnosis of these diseases was performed by medical geneticists without any connection to this study. Samples were collected after abortion of fetuses predicted for having these diseases and after the informed and systematic consent of parents. Skeletal muscle of human SMA patients (n ϭ 6) or subjects affected by diseases unrelated to SMA (n ϭ 5) was collected in the frame of muscle biopsies after the informed consent of patients or parents. SMA patients or fetuses carried homozygous deletion of SMN1 exon 7 (data not shown). All tissue samples were available from the Research Tissues Bank, a Center of Biological Resources located at the PitieSalpetriere Hospital. Samples were obtained from surgical operation (surgery scrap) or from autopsy materials from fetuses (with systematic consent of parents) following the laws and the rules. Tissues have been harvested by an individual who had no connection to the study itself.
RNA extraction, cDNA labeling, and array hybridization. Tissues were dissected and stored at Ϫ80°C. Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's instructions and purified using RNeasy columns (Qiagen). RNA concentration and integrity were assessed by absorbance at 260 and 280 nm and gel electrophoresis. Microarray experiments were performed on mouse samples. cDNA was synthesized from 20 g of RNA and labeled with either cyanine 3 (Cy3) or cyanine 5 (Cy5; Perkin Elmer) using a direct labeling cDNA synthesis kit (Agilent). Cy5-labeled mutant cDNA was then mixed with Cy3-labeled control cDNA, and the mixture was hybridized to mouse microarrays containing ϳ8,400 cDNA probes (G4104A, Agilent) for 17 h at 65°C. The slides were then washed and dried, and images were read using an Agilent DNA microarray scanner (G2565AA). The microarray data are available at the EMBL-European Bioinformatics Institute (EBI) ArrayExpress web site (http://www.ebi.ac.uk/arrayexpress/query/entry) under accession number E-MEXP-131.
Data analysis. For the analysis of microarray experiments, ratio data were extracted from scanned microarray images using Agilent G2567AA Feature Extraction software (v7.5) and processed using Luminator software (Rosetta). A population of control spots was present on each slide and was used to calculate population statistics of spot intensities and background region, using a 99% level of confidence. Normalization was conducted using the software. To assess the significance of the log ratio (level of intensity in Cy5-labeled sample relative to Cy3-labeled sample), and therefore the confidence in the gene's differential expression, the log ratio error and P value were calculated for all features based on an error model. The significance of the feature intensity was calculated using two-sided Student's t-test. A detailed description of algorithms that were utilized can be found at http://www.chem.agilent.com/scripts/literaturePDF.asp?iWHID‫؍‬ 37629.
To determine the reliability of microarray data, dye swap experiments were performed using liver and heart samples of wild-type mouse. cDNA from mouse liver and heart was synthesized and labeled with Cy3 and Cy5, respectively, and vice versa and hybridized following the protocol described above. The relative ratio of each transcript was expressed as log 10 [heart (Cy5): Liver (Cy3)] and compared with that of Ϫlog10 [liver (Cy5): heart (Cy3)]. A total of 3,384 genes were selected based on P value Ͻ 0.02. A high correlation coefficient (98.5%) was observed between the two experiments (Supplemental Material S1; available at the Physiological Genomics web site). 1 To determine the most reliable criteria for two-dimensional cluster and further molecular investigation, correlation between microarray data and real-time quantitative PCR amplification of reverse transcripts was evaluated. For the correlation analysis, the same RNA samples used for microarray experiments were reverse transcribed, and real-time PCR amplification of transcripts was performed. Aldolase was used as the internal control, since no significant difference was observed between control and mutant samples (skeletal muscle or spinal cord; data not shown). A total of 45 microarray data corresponding to 23 genes were examined. Two-fold expression changes in mutant-to-control ratio associated with high signal homogeneity (P value Ͻ 0.02) resulted in 82% correlation between microarray and real-time PCR amplification data. All inconsistent data (8 of 45) were coming from negative mutant-to-control ratio found in microarray data (data not shown; 2 , P ϭ 0.003). To reduce the proportion of false negatives, more stringent criteria were applied. Microarray data were selected when positive fold change was greater than or equal to 2 and negative change was less than or equal to Ϫ3. These criteria resulted in 89% correlation between microarray and real-time PCR amplification data. Data were visualized and analyzed using Luminator software (Rosetta). Two-dimensional clusters were generated using the agglomerative hierarchical clustering algorithm (average link). To update the slide annotation of expressed sequence tags (ESTs; which represented 40% of cDNA loaded on the microarray slide), a search for sequence homology was carried out from gene accession number. Software written with python 2.3 (BioPython module) was elaborated to compare nucleotide sequence with those of the National Center for Biotechnology Information (NCBI) database, using blastN (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/release/2.2.8/netblast-2.2.8-ia32-linux.tar.gz). Sequences with homology Ͼ80% were then validated manually, leading to 18% of unknown sequences. The same procedure was applied to the accession number of known genes loaded onto slides and selected in our study. Among 238 known genes, names were updated for 11 sequences.
Real-time quantitative PCR amplification analysis. cDNA was synthesized from total RNA using an RT reaction. Briefly, 5 g of total RNA were mixed to oligo(dT) (50 M), dATP, dGTP, dCTP, and dTTP (1 mM each). After 5 min of incubation at 65°C, 20 l of 5ϫ first-strand buffer (Invitrogen) and DTT (10 mM), 5 l of RNase out (Invitrogen), and 3 l of Superscript II (Invitrogen) were added to the reaction. Synthesis was achieved by incubating the mix at 42°C for 50 min. Then, the reaction was inactivated by heating at 70°C for 15 min. The cDNAs were stored at Ϫ20°C before being used as template for quantitative PCR. Oligonucleotides were designed using primer express software (Applied Biosystems). Primer sequences of mouse and human genes are shown in Supplemental Material S2. Real-time quantitative PCR was carried out in 96-well plates, using the SYBR Green master mix (Applied Biosystems) according to manufacturer's instructions and processed on an ABI prism 7000 (Applied Biosystems). The thermal conditions used were 2 min at 50°C and 10 min at 95°C, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. For each set of primers, optimal primer concentration was first determined, and then a standard curve using increased dilution of cDNA was established in control tissues. Each reaction was performed at least in duplicate to evaluate the relative level of gene expression in tissue samples. Transcript levels were normalized to that of aldolase, since no difference in aldolase transcript level was observed between control and SMN-deficient tissues (3 mice in each group). ␤-Actin was selected as internal control, since no difference was observed between human control and SMA tissues. All values are means Ϯ SE. Student's t-test was used in statistical analyses.
Immunoblotting experiments. Skeletal muscle of 1-mo-old control (Smn F7/ϩ ) and muscular mutant (HSA-Cre, Smn F7/⌬7 ) mice were rapidly frozen and crushed in liquid nitrogen using a mortar and pestle. Pulverized tissue samples were transferred into 5 vol of a buffer containing 25 mM sodium phosphate (pH 7.2), 5 mM EDTA, and 1% SDS supplemented with protease inhibitor cocktail (Sigma, St Louis, MO) and boiled for 5 min. Protein sample (50 g) was mixed with an equal volume of 2ϫ Laemmli buffer, electrophoresed, and then transferred. For FHL2 and p21 immunodetection, anti-FHL2 (1/1,000; a gift from Dr. Roland Schüle) and anti-p21 (1/1,000; BD Biosciences, San Jose, CA) monoclonal antibodies were used. For actin immunodetection, anti-actin monoclonal antibodies were used (1:10,000; Chemicon International, Temecula, CA). After washes in PBS and 0.05% Tween 20, membranes were incubated with horseradish peroxidase-conjugated secondary antibody (1/5,000 to 1/10,000; Jackson Laboratories, West Grove, PA), and the immune complexes were revealed using chemiluminescent detection reagents (Pierce, Rockford, IL). ) and neuronal mutants (NSECre, Smn F7/F7 ) were analyzed. Twenty-or thirty-day-old mutant and control mice were used for this study. These ages were chosen based on the phenotypic characteristics of both mutants. At 20 days of age, neuronal or muscular mutants did not display any motor defect despite a Cre recombinase activity in Ͼ80% of motor neurons or muscle fibers, respectively (4, 5, 8) . At 30 days of age, both mutants display motor defects associated with marked histological changes in targeted tissues (4, 5, 8) . Microarray analysis was performed on at least three animals of each group. To exclude physiological noise, only genes found to share regulation in at least two of three mutant mice (or 3 of 4) at each age (20 or 30 days old) and in each tissue (skeletal muscle or spinal cord) were retained.
RESULTS

Activation of a high proportion of
On the basis of these criteria, a set of 429 genes that displayed expression changes in either mutant skeletal muscle or spinal cord was selected (Supplemental Materials S3 and S4). Among them, 255 genes were significantly regulated in skeletal muscle of 30-day-old mutant mice and 100 genes in spinal cord of 30-day-old neuronal mutants. The number of genes expressed in response to the SMN defect increased from 20 to 30 days of age in both muscular (3.5-fold, 70 to 255 genes) and neuronal mutants (1.5-fold, 66 to 100 genes), which indicated progression of molecular defects during the disease course (Supplemental Material S4).
To characterize the molecular pathways involved in response to the SMN defect, the regulated genes were subdivided into groups according to the Gene Ontology (GO) classification system (http://www.informatics.jax.org/userdocs/go_help. shtml). For a given functional class, the proportion of genes At right are given the results of RNA quantification shown as the ratio of mutant-to-control expression in mouse and human tissue samples. SM, skeletal muscle; SC, spinal cord; ND, not detectable. *P Ͻ 0.05. . The proportion of genes differentially expressed in neuronal or muscular mutants was similar in several functional classes including cytoskeleton, metabolism, and transcription. However, markedly different proportions of genes involved in inflammation, muscle contraction, or RNA metabolism were observed between mutant skeletal muscle and spinal cord (Supplemental Material S5). The proportion of genes involved in inflammation was higher in mutant spinal cord (14%) than in mutant skeletal muscle (2%). The proportion of genes involved in muscle contraction was markedly lower in mutant spinal cord (1%) than in mutant skeletal muscle (5%), a feature consistent with the expression pattern of these genes restricted to skeletal muscle (Supplemental Materials S4 and S5).
Interestingly, a high proportion of genes (5%, 20 of 429) were involved in pre-mRNA splicing, ribosomal RNA processing, or RNA decay (Table 1 and Supplemental Material S4). Eighteen of them were upregulated and two downregulated (Supplemental Material S4). The proportion of genes involved in RNA metabolism was higher in mutant skeletal muscle (7%) than in mutant spinal cord (2%, Supplemental Material S5). The low proportion of motor neurons with respect to the other cell types in the spinal cord could lead to underestimation of the number of overexpressed genes using a fold change greater than or equal to two. In agreement with this, 10 of 16 genes that were overexpressed in skeletal muscle were also found to be upregulated in spinal cord when using less-stringent criteria (fold change Ն1.3, Fig. 1 ). Real-time PCR analysis of transcripts encoding galectin-3 (Lgals3), embryonic lethal abnormal vision (ELAV)-like protein 1 (Elavl1), Ewing sarcoma homolog (Ewsr1), and pre-mRNA branch site protein p14 (SAP14) showed an expression of these genes in both spinal cord and skeletal muscle of wild-type mice and confirmed their overexpression in mutant mice, in agreement with the microarray data ( Fig. 1 and Table 1) .
With SMN having a role in RNA metabolism in vitro, we determined whether the expression changes of RNA metabolism-related genes were specific to SMN defect. To this end, a gene expression profile was determined in spinal cord of transgenic mice overexpressing the SOD1-G93A gene, a mouse model of amyotrophic lateral sclerosis (ALS) (11) . Fourteen of eighteen RNA metabolism-related genes that were upregulated in the Smn mutants did not display any changes in ALS, indicating that they were specific to the SMN defect ( Figs. 1 and 2) . With the use of real-time PCR analysis, transcript levels of a subset of these genes were evaluated in spinal cord of affected ALS transgenic mice (n ϭ 3, 4 mo old) and confirmed the microarray data (Fig. 2) . These results allowed classifying the genes involved in RNA metabolism into SMN-specific and nonspecific groups (Fig. 1) .
Within the SMN-specific group of genes, eight were overexpressed in mutant skeletal muscle but not spinal cord. To know whether these genes could be activated in response to myofiber degeneration in a nonspecific manner, quantitative analysis of transcripts encoding Elavl1, Ewsr1, and SAP14 was performed in skeletal muscle of mdx mice (n ϭ 3, 4 mo old), a mouse model of Duchenne muscular dystrophy (Fig. 2) . Transcript levels of these genes were similar in mdx and control mice. In contrast, Lgals3, which was upregulated in both Smn mutant and ALS transgenic mice, was also upregulated in mdx, indicating a nonspecific response to tissue damage (Fig. 2) . Therefore, a total of 14 overexpressed genes involved in RNA metabolism were specific to the SMN defect (Fig. 1) . They encode proteins having a role in pre-mRNA splicing, ribosomal RNA processing, or RNA decay ( Table 1) .
Expression of the RNA metabolism-related genes was studied during the disease course of mutant skeletal muscle. At 9 Fig. 3 . Expression analysis of RNA metabolism-related genes in human SMA tissues. Real-time RT-PCR amplification analysis of RNA metabolism-related genes was performed in adult skeletal muscle (A), fetal skeletal muscle (B), and fetal spinal cord (C). In each group, SMA tissues (solid columns) were analyzed and compared with control (open columns). The no. of samples tested for each gene is as follows: human adult skeletal muscle control, n ϭ 5; SMA adult skeletal muscle, n ϭ 6; fetal control skeletal muscle, n ϭ 7; fetal SMA skeletal muscle, n ϭ 3; fetal control spinal cord, n ϭ 5; fetal SMA spinal cord, n ϭ 3. Expression level is shown as the ratio of the target gene to ␤-actin (arbitrary units). *P Ͻ 0.05. nd, Not detectable. Target gene expression was normalized to that of aldolase by using real-time PCR analysis. Then, mutant-to-control ratio (M:C) was determined in skeletal muscle from 9-(n ϭ 2), 20-(n ϭ 4), and 30-day-old mice (n ϭ 4). *P Ͻ 0.05. days of age, the full-length SMN transcripts remain present, although at a low level, in muscular mutants (4) , and transcript levels of RNA metabolism-related genes showed no significant difference compared with wild-type skeletal muscle (Table 2) . At 20 or 30 days of age, the full-length SMN transcripts are no longer detected (4) . Dramatically increased levels of RNA metabolism-related gene transcripts were observed showing a tight correlation between lack of full-length SMN transcripts and upregulation of RNA metabolism-related genes ( Table 2 ). These data indicate that activation of the RNA metabolismrelated genes was an early adaptive event in response to the lack of SMN, a feature in agreement with a role of SMN in RNA metabolism in vivo.
Lack of activation of RNA metabolism-related genes in human SMA tissues. To determine whether activation of RNA metabolism-related genes found in Smn mutant mice occurred in human SMA disease, real-time quantitative PCR amplification analysis of orthologous transcripts was performed in human SMA tissue samples including skeletal muscle and spinal cord. Skeletal muscle (n ϭ 3) and spinal cord samples (n ϭ 3) collected from 10-to 19-wk-old fetuses predicted for having SMA linked to SMN1 mutations were analyzed. Skeletal muscle (n ϭ 7) and spinal cord samples (n ϭ 5) from fetuses having a defect unrelated to neuromuscular disorders were used as controls. ␤-Actin was chosen as internal control, since no difference of expression level was observed between control and SMA samples (data not shown). Seven orthologous genes involved in the RNA metabolism were not activated in SMA compared with control tissues (Fig. 3 and Table 1 ). To determine whether activation of these genes might occur at a later stage of the disease course, skeletal muscles were collected from affected patients (n ϭ 6) or controls (n ϭ 5) and analyzed. Quantitative analysis of transcript levels of the same genes did not reveal any change in SMA compared with control tissues (Fig. 3 and Table 1 ). In addition, the Brunol 3 gene, which was recently shown to be overexpressed in muscle cells from a single SMA patient, was found to have an expression unchanged or even downregulated in human skeletal muscle or spinal cord tissues at either fetal or postnatal stages (1) (Fig. 3) . These data indicate that activation of several RNA metabolism-related genes did not occur in human SMA.
To determine whether the discrepancies between human and mouse transcriptional programs involved other pathways, some genes unrelated to RNA metabolism were investigated. They included the cyclin-dependent kinase inhibitor 1A (p21), four and a half LIM domains 2 (FHL2), and stathmin-like protein 4 (STMN4), which were deregulated in mutant mice (Supplemental Material S4 and Fig. 4) . They encode proteins involved in various molecular pathways including cell cycle withdrawal (12) , cell differentiation (18), or microtubule dynamics (24) . Expression changes of these genes were confirmed by the analysis of either transcripts or proteins or both in mouse mutant tissues (Fig. 4) . In human SMA tissues, quantitative PCR analysis of orthologous transcripts revealed similar changes (Fig. 4) .
DISCUSSION
This study was able to define the pattern of transcriptional changes resulting from the SMN defect only. Indeed, skeletal muscle was collected from the muscular mutant in which the Smn exon 7 deletion was directed to skeletal muscle and not to neurons (4) , and from spinal cord of the neuronal mutant carrying the same mutation in neurons but not in skeletal muscle (8) . Therefore, our approach avoided collecting transcriptional adaptations of skeletal muscle to motor neuron degeneration or adaptations of spinal cord to skeletal muscle necrosis.
Of special interest was the observation of an activation of genes involved in RNA metabolism. They represent a high proportion of regulated genes in Smn mutant mice (5%). Excluding those found in ALS or mdx mice, which represent nonspecific responses, 14 genes were upregulated in response to SMN defect. Quantitative RT-PCR analysis confirmed the microarray data and showed that activation of this pathway was an early event during disease course. In vitro experiments or cell culture systems have shown that SMN plays an essential role in RNA metabolism (20, 21, 23, 26) . In Smn mutant mice, the overexpression of genes involved in this process and/or interacting with SMN (such as Ewing sarcoma homolog, 28) might represent an adaptive response of RNA processing machinery to the lack of a component involved in the same process. However, activation of this pathway is not sufficient to prevent myofiber or neuron degeneration. These results provide, therefore, the first indirect evidence for a role of SMN in RNA metabolism in vivo.
Importantly, no overexpression of orthologous RNA metabolism-related genes specific to SMN defect was found in skeletal muscle or spinal cord of human SMA samples at either fetal or postnatal stages. How do we explain theses discrepancies between human and mouse tissues mutated for SMN? In skeletal muscle of 9-day-old mutant mice, marked reduction but not complete absence of full-length SMN transcripts is observed without any significant changes of the RNA metabolism-related genes. At later stages (20 or 30 days of age), Cre-mediated deletion of Smn exon 7 is completed, and fulllength Smn transcripts are no longer detected. Then, an overexpression of RNA metabolism-related genes is observed. These data strongly suggest that this transcriptional program is activated in response to the lack but not marked reduction of full-length SMN in vivo. In human SMA, SMN2, a highly homologous copy of the SMN1 gene, remains present, encoding a low level of full-length SMN transcripts that are translated into a functional protein (16) . We can hypothesize that full-length SMN transcripts and proteins, at a low level, are likely sufficient for the RNA processing, while its complete lack would be deleterious, leading to an activation of the RNA processing machinery that could be regarded as a compensatory mechanism. Anderson et al. (1) have shown an upregulation of Brunol 3, an RNA-binding protein, in mutant mice or myoblast culture from an SMA patient. The analysis of Brunol 3 transcript level in either fetal or postnatal skeletal muscle or spinal cord from human SMA patients was not able to reproduce these results. Altogether, these results provide strong evidence for an involvement of the RNA processing in mouse but not human tissues mutated for SMN, which raises the question of whether this pathway is defective in human SMA.
Although these results showed important discrepancies in the transcriptional program of RNA metabolism-related genes between human and mouse tissues mutated for SMN, other pathways involving p21, FHL2, and STMN4 genes (12, 18, 24) displayed similar expression changes in both murine and human SMA. The role that these genes may have in SMA pathogenesis will require in-depth analysis of the gene products in SMA. The availability of biomarkers specific to SMA should contribute to better evaluation of natural human SMA course and should be very helpful for accurate estimation of the potential benefit of therapeutics in SMA.
